Several mRNA vaccine trials found a debilitating side effect, and now the Trump administration is cutting funding for more ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

(Reuters) -The U.S. Centers for Disease Control and Prevention is still recommending COVID-19 vaccines for healthy children, ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

A new drug combination has been shown to double survival time for patients with a particularly aggressive type of colorectal ...

There have been important recent advances in the management of Crohn's disease, including new classes of biological or small molecule therapies, an appreciation that endoscopic mucosal healing results ...

The Centers for Disease Control and Prevention says children without underlying health conditions "may receive" a COVID-19 ...

The U.S. Centers for Disease Control and Prevention is still recommending COVID-19 vaccines for healthy children, according ...